<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125428">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469650</url>
  </required_header>
  <id_info>
    <org_study_id>419-11</org_study_id>
    <nct_id>NCT01469650</nct_id>
  </id_info>
  <brief_title>Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants</brief_title>
  <official_title>Serum 25(OH)D Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aims of this study are to determine levels of vitamin D supplementation to
      achieve goal serum 25(OH)D levels of 30 ng/mL, and to define serum 25(OH)D levels required
      to achieve suppression of parathyroid hormone in preterm newborn infants hospitalized in the
      Nebraska Medical Center Newborn Intensive Care Nursery (NICU). In this randomized,
      controlled trial, infants 23 weeks gestational age or greater will be randomized to two
      different levels of vitamin D supplementation: 400 IU vitamin D3/day, or 800 IU vitamin
      D3/day. As an exploratory aim, vitamin D binding protein levels (VDBP) will also be
      quantified in these infants.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25(OH)D Levels</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parathyroid Hormone Levels</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Premature Infants</condition>
  <arm_group>
    <arm_group_label>400 IU/day vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 400 IU/day of vitamin D3, as per current unit policy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 IU/day vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 800 IU/day vitamin D3</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferal</intervention_name>
    <description>400 IU/day</description>
    <arm_group_label>400 IU/day vitamin D</arm_group_label>
    <other_name>vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>cholecalciferol</intervention_name>
    <description>800 IU/day D3</description>
    <arm_group_label>800 IU/day vitamin D3</arm_group_label>
    <other_name>vitamin D3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  NICU hospitalized infants

          -  23-32 weeks gestation

        Exclusion Criteria:

          -  congential anomalies

          -  disorders of calcium metabolism

          -  inborn error of metabolism

          -  kidney disease

          -  liver disease

          -  use of steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Corrine K Hanson, PhD</last_name>
    <phone>402-559-3658</phone>
    <email>ckhanson@unmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrine K Hanson, PhD</last_name>
      <phone>402-559-3658</phone>
      <email>ckhanson@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Corrine Hanson, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Anderson Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Armas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 9, 2011</lastchanged_date>
  <firstreceived_date>November 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Corrine K. Hanson</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>vitamin D3</keyword>
  <keyword>prematurity</keyword>
  <keyword>parathyroid hormone</keyword>
  <keyword>25(OH)D</keyword>
  <keyword>NICU hospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
